News from arena pharmaceuticals, inc

Jul 10, 2014, 08:00 ET

Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract...

Jun 13, 2014, 08:00 ET

Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 2014...

Jun 03, 2014, 08:00 ET

Arena Pharmaceuticals Initiates Phase 1b Clinical Trial of APD334 for Autoimmune Diseases

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a...

May 27, 2014, 08:00 ET

Arena Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Jefferies 2014...

May 12, 2014, 16:03 ET

Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2014 Financial Results

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31,...

May 09, 2014, 08:00 ET

Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ® (lorcaserin HCl) CIV by 50%

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai plans to add more than 200 new contract sales representatives to its...

May 05, 2014, 08:00 ET

Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, May 12

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report first quarter 2014 financial results...

Apr 14, 2014, 08:33 ET

Arena Pharmaceuticals Reports Eisai's Launch of National Television Advertising Campaign for BELVIQ® (lorcaserin HCl) CIV for Chronic Weight Management

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has launched a national television advertising campaign for...

Feb 27, 2014, 16:22 ET

Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2013 Financial Results

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year...

Feb 20, 2014, 08:00 ET

Arena Pharmaceuticals to Provide Corporate Update and Report Financial Results on Thursday, February 27

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and report fourth quarter and full year 2013...

Feb 13, 2014, 02:00 ET

Arena Pharmaceuticals annonce qu'elle a déposé une demande d'autorisation de mise sur le marché pour BELVIQ® (lorcaserin HCl) au Brésil

 Arena Pharmaceuticals GmbH, une filiale d'Arena Pharmaceuticals, Inc. (NASDAQ : ARNA), a annoncé aujourd'hui qu'Eisai Laboratorios...

Feb 13, 2014, 02:00 ET

Arena Pharmaceuticals verkündet die Beantragung zur Marktzulassung von BELVIQ® (lorcaserin HCl) in Brasilien

  Arena Pharmaceuticals GmbH, die schweizerische Tochtergesellschaft von Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), hat heute...

Feb 12, 2014, 08:00 ET

Arena Pharmaceuticals Announces Filing for Marketing Authorization of BELVIQ® (lorcaserin HCl) in Brazil

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Laboratorios Ltda., a subsidiary of Eisai Inc., has filed for marketing...

Feb 10, 2014, 08:00 ET

Arena Pharmaceuticals Reports Coverage for BELVIQ® (lorcaserin HCl) CIV Now Greater Than 50% of Insured Commercial Lives

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai has secured improved patient access of BELVIQ®...

Feb 05, 2014, 08:00 ET

Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at two upcoming investor...

Jan 06, 2014, 08:00 ET

Arena Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 32nd Annual J.P....

Nov 27, 2013, 08:00 ET

Arena Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 25th Annual...

Nov 18, 2013, 08:00 ET

BELVIQ® (lorcaserin HCl) CIV Data to be Presented at American Heart Association 2013 Scientific Sessions

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a new data analysis from the BELVIQ® (lorcaserin HCl)...

Nov 13, 2013, 02:00 ET

Arena Pharmaceuticals GmbH erweitert Marketing- und Liefervereinbarung für BELVIQ® (Lorcaserin HCl) mit Eisai zur Abdeckung der meisten Länder weltweit

-- Dieser Schritt dient als Wachstumsmotor für den Hauptsitz in Zofingen als weltweites Produktions- und Vertriebszentrum für das neue...

Nov 13, 2013, 02:00 ET

Arena Pharmaceuticals GmbH élargit son contrat de commercialisation et de fourniture de BELVIQ® (hydrochlorure de lorcaserine) avec Eisai pour couvrir pratiquement tous les pays dans le monde entier

-- La transaction est le catalyseur de la croissance des opérations basées à Zofingen en tant que centre mondial de fabrication et...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer